share_log

Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135

Goldman Sachs Initiates Coverage On Vaxcyte With Buy Rating, Announces Price Target of $135

高盛對Vaxcyte啓動了覆蓋,並給予買入評級,宣佈目標價爲135美元。
Benzinga ·  06:51  · 評級/大行評級

Goldman Sachs analyst Chris Shibutani initiates coverage on Vaxcyte (NASDAQ:PCVX) with a Buy rating and announces Price Target of $135.

高盛分析師克里斯·希布塔尼開始對Vaxcyte(納斯達克股票代碼:PCVX)進行報道,評級爲買入,並宣佈目標股價爲135美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論